Jump to
Administrator Info
Email: endofixer@umn.edu
Mail: 420 Delaware Street SE
MMC 101
Minneapolis, MN 55455
Summary
Dr. Amir Moheet graduated from Dow Medical College in Karachi, Pakistan. He completed his Internal Medicine residency training and was chief resident at State University of New York at Buffalo, NY. He completed his Endocrinology fellowship from University of Minnesota in 2012. Dr. Moheet is currently an Associate Professor in Division of Endocrinology, Diabetes and Metabolism at University of Minnesota. He is actively engaged in clinical and translational research. His research is focused on examining the effects of diabetes and its complications on brain metabolism, structure and function. His clinical and research interests also include cystic fibrosis related diabetes.
MD, Dow Medical College
Moheet A, Emir UE, Terpstra M, Kumar A, Eberly LE, Seaquist ER, Oz G. Initial experience with seven tesla magnetic resonance spectroscopy of hypothalamic GABA during hyperinsulinemic euglycemia and hypoglycemia in healthy humans. Magn Reson Med. 2014 Jan;71(1):12-8. PMID: 23423963; PMCID: PMC3665652,
Moheet A, Emir UE, Terpstra M, Kumar A, Eberly LE, Seaquist ER, Oz G. Initial experience with seven tesla magnetic resonance spectroscopy of hypothalamic GABA during hyperinsulinemic euglycemia and hypoglycemia in healthy humans. Magn Reson Med. 2014 Jan;71(1):12-8. PMID: 23423963; PMCID: PMC3665652,
Moheet A, Mangia S, Kumar A, Tesfaye N, Eberly LE, Bai Y, Kubisiak K and Seaquist ER Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial. Journal for diabetes and its complications. 2015 Nov-Dec;29(8):1277-82. PMID: 26345338; PMCID: PMC4871128,
Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015 Sep;1353:60-71; PMID: 26132277; PMCID: PMC4837888,
Moheet, A., Beisang, D., Zhang, L., Sagel, S., VanDalfsen, J., Heltshe, S., Frederick, C., Mann, M., Antos, N., Billings, J., Rowe, S., & Moran, A. (2020). PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros 2020 Sep 8;S1569-1993(20)30862-6.,
Elected for lifetime membership in the University of Minnesota Office of Academic Clinical Affairs Academy for Excellence in Team Science, 2019
Selected in the EnVision CF: Emerging Leaders in Cystic Fibrosis Endocrinology Program, Cystic Fibrosis Foundation, 2016
Mpls St.Paul Magazine, 2015
Type 1 and type 2 diabetes, General Endocrinology, Cystic fibrosis related diabetes